Skip to content
The Cluster Headache Support Group
The Cluster Headache Support Group

Patient-directed support, education, research, and advocacy

  • Register
  • Login
  • Password Reset
Secondary Navigation Menu
Menu
  • Guides
    • Cluster Headache Basics
    • Sumatriptan
    • Oxygen
    • Disability
    • Coping Strategies
  • Education
    • What is Cluster Headache?
    • What are Shadows?
    • FAQs
    • Journal Articles
  • Treatment Options
    • Abortives
    • Preventives
    • Bridging Therapies
    • Neuromodulation
    • Alternative Therapies
  • Resources
    • Reliable Sources of Information about Headache Disorders
    • Finding the Right Doctor
    • Getting the Right Diagnosis
    • Getting Help in a Crisis
    • Resources to Download
    • Home Oxygen Prescribing Guide and Resource Kit for Physicians
    • The KIP Scale
    • Comparative Pain Scale
    • Clinical Trials
  • CHSG Store
    • CHSG Swag
    • Printed Materials
    • Handcrafted items
  • Account
    • Register
    • Login
    • Password Reset
  • About CHSG
    • Awareness & Advocacy
    • Fundraising
    • Strategic Plan
    • Current Projects
    • Research
    • Collaborative Partnerships
    • Terms and Conditions
    • Contact Us
The Cluster Headache Support Group > Journal Articles > Pathophysiology > COVID-19

COVID-19

Risks Associated with COVID-19 Infection and Vaccination for Headache Disorders

2021-09-25
By: CHSG Admin
On: September 25, 2021
In: COVID-19

Very little is known about the effect of any COVID-19 vaccine on cluster headache. What little research we have has been done on migraine and tension-type headache. We don’t have answers to all the questions. That doesn’t mean we don’t know anything.Read More →

Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study

2021-09-25
By: CHSG Admin
On: September 25, 2021
In: COVID-19, Pathophysiology
With: 0 Comments

The novel coronavirus SARS-CoV-2 causes the infectious disease COVID-19. Newly developed mRNA vaccines can prevent the spread of the virus. Headache is the most common neurological symptom in over 50% of those vaccinated.Read More →

Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine

2021-09-25
By: CHSG Admin
On: September 25, 2021
In: COVID-19
With: 0 Comments

This analysis characterizes the immunogenicity profile of galcanezumab, a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and inhibits its activity, in phase 3 migraine trials.Read More →

Terms and Conditions Designed using Magazine Hoot Premium. Powered by WordPress.